Citigroup
VIR icon

Citigroup’s Vir Biotechnology VIR Stock Holding History

Citigroup’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.23M Sell
218,419
-37,721
-15% -$359K ﹤0.01% 2852
2026
Q1 		$2.3M Sell
256,140
-55,147
-18% -$439K ﹤0.01% 2585
2025
Q4 		$1.88M Sell
311,287
-12,238
-4% -$72.9K ﹤0.01% 2703
2025
Q3 		$1.85M Sell
323,525
-92,426
-22% -$473K ﹤0.01% 2740
2025
Q2 		$2.1M Buy
415,951
+155,433
+60% +$833K ﹤0.01% 2608
2025
Q1 		$1.69M Buy
260,518
+76,201
+41% +$678K ﹤0.01% 2856
2024
Q4 		$1.35M Buy
184,317
+69,899
+61% +$551K ﹤0.01% 3124
2024
Q3 		$857K Buy
114,418
+29,547
+35% +$257K ﹤0.01% 3372
2024
Q2 		$755K Sell
84,871
-1,039,860
-92% -$9.97M ﹤0.01% 3103
2024
Q1 		$11.4M Buy
1,124,731
+918,710
+446% +$9.36M 0.01% 1178
2023
Q4 		$2.07M Sell
206,021
-51,432
-20% -$470K ﹤0.01% 2211
2023
Q3 		$2.41M Buy
257,453
+100,975
+65% +$1.44M ﹤0.01% 1869
2023
Q2 		$3.84M Sell
156,478
-142,619
-48% -$3.58M ﹤0.01% 1669
2023
Q1 		$6.96M Buy
299,097
+106,436
+55% +$2.72M ﹤0.01% 1320
2022
Q4 		$4.88M Sell
192,661
-126,119
-40% -$3.09M ﹤0.01% 1481
2022
Q3 		$6.15M Buy
318,780
+97,130
+44% +$2.47M ﹤0.01% 1433
2022
Q2 		$5.65M Buy
221,650
+174,980
+375% +$4.09M ﹤0.01% 1469
2022
Q1 		$1.2M Sell
46,670
-66,592
-59% -$1.98M ﹤0.01% 2789
2021
Q4 		$4.74M Buy
113,262
+2,448
+2% +$95.9K ﹤0.01% 1874
2021
Q3 		$4.82M Buy
110,814
+7,325
+7% +$317K ﹤0.01% 1851
2021
Q2 		$4.89M Buy
103,489
+8,298
+9% +$377K ﹤0.01% 1905
2021
Q1 		$4.88M Buy
95,191
+73,869
+346% +$3.98M ﹤0.01% 1803
2020
Q4 		$571K Buy
21,322
+15,215
+249% +$495K ﹤0.01% 4082
2020
Q3 		$209K Sell
6,107
-4,800
-44% -$207K ﹤0.01% 4585
2020
Q2 		$447K Buy
10,907
+8,262
+312% +$277K ﹤0.01% 4360
2020
Q1 		$91K Buy
2,645
+1,200
+83% +$32.3K ﹤0.01% 5413
2019
Q4 		$18K Buy
+1,445
New +$19.4K ﹤0.01% 6984

Other funds holding VIR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Citigroup's VIR Position: Q2 2026 in Review

Citigroup reduced its Vir Biotechnology (VIR) stake by 15% in Q2 2026, selling an estimated $359K and leaving 218,419 shares worth $2.23M. The position accounts for ﹤0.01% of the portfolio, ranked #2852.

Citigroup first reported a position in VIR in Q4 2019 and has held it in 27 quarters since. The position peaked at $11.4M in Q1 2024. 237 funds tracked by Wall St. Rank hold VIR as of Q2 2026.

  • Citigroup held 218,419 shares of Vir Biotechnology worth $2.23M as of Q2 2026.
  • Citigroup sold 37,721 Vir Biotechnology shares in Q2 2026, an estimated $359K.
  • Vir Biotechnology made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #2852 holding.
  • Citigroup first reported a position in Vir Biotechnology in Q4 2019 and has held it in 27 quarters since.
  • Citigroup's Vir Biotechnology position peaked at $11.4M in Q1 2024.
  • 237 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.